Location Directory

Clinical trials in Baltimore, Maryland

This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13749

Shown on this page

Current sort

Institutions in Baltimore

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Johns Hopkins

Live official records

Open in full search

Conditions: Lactation, Inflammatory Bowel Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 3 Weeks and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Glenview, Illinois • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Medical Chart Review; Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 2,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 630
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 405 more

Conditions: Symptomatic Genetic Dilated Cardiomyopathy
Interventions: danicamtiv, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Vestibular Schwannoma
Interventions: AAVAnc80-antiVEGF via Akouos Delivery Device; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more

Conditions: Corneal Ulcer
Interventions: Mesenchymal Stromal Cells, Control Solution; Biological · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 904 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more

Conditions: Dengue
Interventions: Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 85
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more

Conditions: Treatment Resistant Depression
Interventions: Vagus Nerve Stimulation (VNS); Device
Lead sponsor: LivaNova; Industry
Eligibility: 18 Years and older
Enrollment: 6,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 101
States / cities: Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more

Conditions: Healthy Participants
Interventions: Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo; Biological · Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 49 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy; Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 45 Years to 70 Years
Enrollment: 9,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2065
U.S. locations: 484
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more

Conditions: Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Duarte, California • Palo Alto, California • Tampa, Florida + 7 more

Clinical trials in Baltimore, Maryland

Filter and sort this location

Institutions in Baltimore

Live official records

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab